JP2015505557A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015505557A5 JP2015505557A5 JP2014555561A JP2014555561A JP2015505557A5 JP 2015505557 A5 JP2015505557 A5 JP 2015505557A5 JP 2014555561 A JP2014555561 A JP 2014555561A JP 2014555561 A JP2014555561 A JP 2014555561A JP 2015505557 A5 JP2015505557 A5 JP 2015505557A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- subject
- cancer
- composition
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 225
- 229940123237 Taxane Drugs 0.000 claims description 149
- 206010028980 Neoplasm Diseases 0.000 claims description 124
- 201000011510 cancer Diseases 0.000 claims description 119
- 239000000203 mixture Substances 0.000 claims description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 24
- 208000035475 disorder Diseases 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 13
- 208000024891 symptom Diseases 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 206010006187 Breast cancer Diseases 0.000 claims description 7
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 208000030507 AIDS Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 2
- 230000003511 endothelial effect Effects 0.000 claims description 2
- 230000002792 vascular Effects 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims 5
- 206010020772 Hypertension Diseases 0.000 claims 5
- 208000003906 hydrocephalus Diseases 0.000 claims 5
- 201000001320 Atherosclerosis Diseases 0.000 claims 4
- 206010019233 Headaches Diseases 0.000 claims 4
- 208000006011 Stroke Diseases 0.000 claims 4
- 231100000869 headache Toxicity 0.000 claims 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 4
- 206010019280 Heart failures Diseases 0.000 claims 3
- 208000032843 Hemorrhage Diseases 0.000 claims 3
- 208000023105 Huntington disease Diseases 0.000 claims 3
- 201000009906 Meningitis Diseases 0.000 claims 3
- 208000012902 Nervous system disease Diseases 0.000 claims 3
- 208000008589 Obesity Diseases 0.000 claims 3
- 208000020307 Spinal disease Diseases 0.000 claims 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 3
- 230000000740 bleeding effect Effects 0.000 claims 3
- 210000003169 central nervous system Anatomy 0.000 claims 3
- 208000030159 metabolic disease Diseases 0.000 claims 3
- 235000020824 obesity Nutrition 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 206010002329 Aneurysm Diseases 0.000 claims 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 2
- 206010036618 Premenstrual syndrome Diseases 0.000 claims 2
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 claims 2
- 206010047115 Vasculitis Diseases 0.000 claims 2
- 239000002327 cardiovascular agent Substances 0.000 claims 2
- 229940125692 cardiovascular agent Drugs 0.000 claims 2
- 208000015114 central nervous system disease Diseases 0.000 claims 2
- 230000002490 cerebral effect Effects 0.000 claims 2
- 206010008118 cerebral infarction Diseases 0.000 claims 2
- 208000026106 cerebrovascular disease Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 239000002934 diuretic Substances 0.000 claims 2
- 206010014599 encephalitis Diseases 0.000 claims 2
- 239000003527 fibrinolytic agent Substances 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 208000031225 myocardial ischemia Diseases 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 208000020431 spinal cord injury Diseases 0.000 claims 2
- 229960000103 thrombolytic agent Drugs 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000022316 Arachnoid cyst Diseases 0.000 claims 1
- 206010003101 Arnold-Chiari Malformation Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 206010048623 Atrial hypertrophy Diseases 0.000 claims 1
- 206010061666 Autonomic neuropathy Diseases 0.000 claims 1
- 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 208000014644 Brain disease Diseases 0.000 claims 1
- 206010048962 Brain oedema Diseases 0.000 claims 1
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 1
- 208000006029 Cardiomegaly Diseases 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 208000014912 Central Nervous System Infections Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 108091006146 Channels Proteins 0.000 claims 1
- 208000015321 Chiari malformation Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000006561 Cluster Headache Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 208000005189 Embolism Diseases 0.000 claims 1
- 206010014612 Encephalitis viral Diseases 0.000 claims 1
- 208000032274 Encephalopathy Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000007530 Essential hypertension Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 208000010496 Heart Arrest Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 208000026350 Inborn Genetic disease Diseases 0.000 claims 1
- 208000027601 Inner ear disease Diseases 0.000 claims 1
- 208000003618 Intervertebral Disc Displacement Diseases 0.000 claims 1
- 206010050296 Intervertebral disc protrusion Diseases 0.000 claims 1
- 201000008450 Intracranial aneurysm Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 208000000172 Medulloblastoma Diseases 0.000 claims 1
- 206010027202 Meningitis bacterial Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 206010028570 Myelopathy Diseases 0.000 claims 1
- 208000002033 Myoclonus Diseases 0.000 claims 1
- 208000024080 Myopic macular degeneration Diseases 0.000 claims 1
- 208000003019 Neurofibromatosis 1 Diseases 0.000 claims 1
- 208000024834 Neurofibromatosis type 1 Diseases 0.000 claims 1
- 102000007517 Neurofibromin 2 Human genes 0.000 claims 1
- 108010085839 Neurofibromin 2 Proteins 0.000 claims 1
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 claims 1
- 206010029279 Neurogenic bladder Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033664 Panic attack Diseases 0.000 claims 1
- 206010069588 Parasitic encephalitis Diseases 0.000 claims 1
- 208000031481 Pathologic Constriction Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038934 Retinopathy proliferative Diseases 0.000 claims 1
- 201000004239 Secondary hypertension Diseases 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- 208000022292 Tay-Sachs disease Diseases 0.000 claims 1
- 206010043269 Tension headache Diseases 0.000 claims 1
- 208000008548 Tension-Type Headache Diseases 0.000 claims 1
- 208000001435 Thromboembolism Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 208000032109 Transient ischaemic attack Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 206010044696 Tropical spastic paresis Diseases 0.000 claims 1
- 208000026911 Tuberous sclerosis complex Diseases 0.000 claims 1
- 206010046996 Varicose vein Diseases 0.000 claims 1
- 206010053648 Vascular occlusion Diseases 0.000 claims 1
- 206010047139 Vasoconstriction Diseases 0.000 claims 1
- 206010047295 Ventricular hypertrophy Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 239000004004 anti-anginal agent Substances 0.000 claims 1
- 229940124345 antianginal agent Drugs 0.000 claims 1
- 239000003416 antiarrhythmic agent Substances 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 229940030600 antihypertensive agent Drugs 0.000 claims 1
- 229940127218 antiplatelet drug Drugs 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 206010003074 arachnoiditis Diseases 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 210000001367 artery Anatomy 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 230000001746 atrial effect Effects 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 201000009904 bacterial meningitis Diseases 0.000 claims 1
- 208000034158 bleeding Diseases 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 230000005821 brain abnormality Effects 0.000 claims 1
- 208000006752 brain edema Diseases 0.000 claims 1
- 239000000480 calcium channel blocker Substances 0.000 claims 1
- 210000004413 cardiac myocyte Anatomy 0.000 claims 1
- 239000000496 cardiotonic agent Substances 0.000 claims 1
- 210000001168 carotid artery common Anatomy 0.000 claims 1
- 210000003164 cauda equina Anatomy 0.000 claims 1
- 208000010353 central nervous system vasculitis Diseases 0.000 claims 1
- 201000001883 cholelithiasis Diseases 0.000 claims 1
- 208000018912 cluster headache syndrome Diseases 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 201000003083 communicating hydrocephalus Diseases 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 238000007887 coronary angioplasty Methods 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 230000003412 degenerative effect Effects 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 210000003414 extremity Anatomy 0.000 claims 1
- 208000020694 gallbladder disease Diseases 0.000 claims 1
- 208000016361 genetic disease Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 210000002837 heart atrium Anatomy 0.000 claims 1
- 230000001631 hypertensive effect Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000004630 mental health Effects 0.000 claims 1
- 210000001259 mesencephalon Anatomy 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 230000001452 natriuretic effect Effects 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 208000002761 neurofibromatosis 2 Diseases 0.000 claims 1
- 208000022032 neurofibromatosis type 2 Diseases 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 239000002840 nitric oxide donor Substances 0.000 claims 1
- 201000003077 normal pressure hydrocephalus Diseases 0.000 claims 1
- 201000011107 obstructive hydrocephalus Diseases 0.000 claims 1
- 230000000399 orthopedic effect Effects 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 239000003229 sclerosing agent Substances 0.000 claims 1
- 201000002859 sleep apnea Diseases 0.000 claims 1
- 208000005198 spinal stenosis Diseases 0.000 claims 1
- 230000036262 stenosis Effects 0.000 claims 1
- 208000037804 stenosis Diseases 0.000 claims 1
- 201000010875 transient cerebral ischemia Diseases 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
- 208000006961 tropical spastic paraparesis Diseases 0.000 claims 1
- 208000009999 tuberous sclerosis Diseases 0.000 claims 1
- 208000027185 varicose disease Diseases 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- 208000021331 vascular occlusion disease Diseases 0.000 claims 1
- 230000025033 vasoconstriction Effects 0.000 claims 1
- 229940124549 vasodilator Drugs 0.000 claims 1
- 239000003071 vasodilator agent Substances 0.000 claims 1
- 201000002498 viral encephalitis Diseases 0.000 claims 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 56
- 238000011282 treatment Methods 0.000 description 49
- 238000002512 chemotherapy Methods 0.000 description 43
- 239000002246 antineoplastic agent Substances 0.000 description 42
- 206010039491 Sarcoma Diseases 0.000 description 21
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 18
- 229940127089 cytotoxic agent Drugs 0.000 description 16
- 208000033808 peripheral neuropathy Diseases 0.000 description 14
- 206010035226 Plasma cell myeloma Diseases 0.000 description 13
- 230000001394 metastastic effect Effects 0.000 description 13
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 12
- 201000001119 neuropathy Diseases 0.000 description 12
- 230000007823 neuropathy Effects 0.000 description 12
- 229940041181 antineoplastic drug Drugs 0.000 description 11
- 206010038111 Recurrent cancer Diseases 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 206010061289 metastatic neoplasm Diseases 0.000 description 10
- 201000000050 myeloid neoplasm Diseases 0.000 description 9
- 229910052697 platinum Inorganic materials 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 8
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 7
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 7
- 229940100198 alkylating agent Drugs 0.000 description 7
- 239000002168 alkylating agent Substances 0.000 description 7
- 229940045799 anthracyclines and related substance Drugs 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 7
- 208000004235 neutropenia Diseases 0.000 description 7
- 201000002528 pancreatic cancer Diseases 0.000 description 7
- 208000008443 pancreatic carcinoma Diseases 0.000 description 7
- 210000000440 neutrophil Anatomy 0.000 description 6
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 5
- 108010082126 Alanine transaminase Proteins 0.000 description 5
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 5
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 5
- 206010033128 Ovarian cancer Diseases 0.000 description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 description 5
- 229940122803 Vinca alkaloid Drugs 0.000 description 5
- 230000000340 anti-metabolite Effects 0.000 description 5
- 229940100197 antimetabolite Drugs 0.000 description 5
- 239000002256 antimetabolite Substances 0.000 description 5
- 206010017758 gastric cancer Diseases 0.000 description 5
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 230000002062 proliferating effect Effects 0.000 description 5
- 201000011549 stomach cancer Diseases 0.000 description 5
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 5
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 4
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 4
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 4
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 4
- 201000008808 Fibrosarcoma Diseases 0.000 description 4
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 4
- 206010022095 Injection Site reaction Diseases 0.000 description 4
- 108010044467 Isoenzymes Proteins 0.000 description 4
- 206010067125 Liver injury Diseases 0.000 description 4
- 208000034578 Multiple myelomas Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 229960003957 dexamethasone Drugs 0.000 description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 4
- 231100000234 hepatic damage Toxicity 0.000 description 4
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 4
- 230000008818 liver damage Effects 0.000 description 4
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 3
- 206010055113 Breast cancer metastatic Diseases 0.000 description 3
- 206010052358 Colorectal cancer metastatic Diseases 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 3
- 206010062904 Hormone-refractory prostate cancer Diseases 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 208000007766 Kaposi sarcoma Diseases 0.000 description 3
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 3
- 229930012538 Paclitaxel Natural products 0.000 description 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 3
- 108090000340 Transaminases Proteins 0.000 description 3
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 229960001573 cabazitaxel Drugs 0.000 description 3
- BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 229960003668 docetaxel Drugs 0.000 description 3
- 230000009610 hypersensitivity Effects 0.000 description 3
- 238000011221 initial treatment Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229950005692 larotaxel Drugs 0.000 description 3
- SEFGUGYLLVNFIJ-QDRLFVHASA-N larotaxel dihydrate Chemical compound O.O.O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@@]23[C@H]1[C@@]1(CO[C@@H]1C[C@@H]2C3)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 SEFGUGYLLVNFIJ-QDRLFVHASA-N 0.000 description 3
- 229960001592 paclitaxel Drugs 0.000 description 3
- 150000003230 pyrimidines Chemical class 0.000 description 3
- 230000000306 recurrent effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
- 229960003433 thalidomide Drugs 0.000 description 3
- 102000014898 transaminase activity proteins Human genes 0.000 description 3
- 201000003076 Angiosarcoma Diseases 0.000 description 2
- 208000006619 Cytochrome P-450 CYP2C8 Inhibitors Diseases 0.000 description 2
- 201000001342 Fallopian tube cancer Diseases 0.000 description 2
- 208000013452 Fallopian tube neoplasm Diseases 0.000 description 2
- 208000002633 Febrile Neutropenia Diseases 0.000 description 2
- 208000001258 Hemangiosarcoma Diseases 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 208000018142 Leiomyosarcoma Diseases 0.000 description 2
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 2
- 206010034620 Peripheral sensory neuropathy Diseases 0.000 description 2
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 230000003474 anti-emetic effect Effects 0.000 description 2
- 239000002111 antiemetic agent Substances 0.000 description 2
- 229940125683 antiemetic agent Drugs 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 229940125715 antihistaminic agent Drugs 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 239000000938 histamine H1 antagonist Substances 0.000 description 2
- 206010024627 liposarcoma Diseases 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 208000012804 lymphangiosarcoma Diseases 0.000 description 2
- 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 description 2
- 208000029974 neurofibrosarcoma Diseases 0.000 description 2
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 2
- 201000002628 peritoneum cancer Diseases 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229950008882 polysorbate Drugs 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
- 201000005572 sensory peripheral neuropathy Diseases 0.000 description 2
- 206010042863 synovial sarcoma Diseases 0.000 description 2
- -1 taxanes Substances 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- 244000003416 Asparagus officinalis Species 0.000 description 1
- 235000005340 Asparagus officinalis Nutrition 0.000 description 1
- 0 CC(C)C(CC*(C)OCCC(C)(C)C(NC(CSC(CC1)C1SCC(C(C)=O)NC(C)C)C(C*)=O)=O)=O Chemical compound CC(C)C(CC*(C)OCCC(C)(C)C(NC(CSC(CC1)C1SCC(C(C)=O)NC(C)C)C(C*)=O)=O)=O 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- 102000002263 Cytochrome P-450 CYP2C8 Human genes 0.000 description 1
- 108010000561 Cytochrome P-450 CYP2C8 Proteins 0.000 description 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 208000017891 HER2 positive breast carcinoma Diseases 0.000 description 1
- 208000005726 Inflammatory Breast Neoplasms Diseases 0.000 description 1
- 206010021980 Inflammatory carcinoma of the breast Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000035327 Oestrogen receptor positive breast cancer Diseases 0.000 description 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 206010070308 Refractory cancer Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- RGHILYZRVFRRNK-UHFFFAOYSA-N anthracene-1,2-dione Chemical compound C1=CC=C2C=C(C(C(=O)C=C3)=O)C3=CC2=C1 RGHILYZRVFRRNK-UHFFFAOYSA-N 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 230000035572 chemosensitivity Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 238000002681 cryosurgery Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 201000007280 estrogen-receptor negative breast cancer Diseases 0.000 description 1
- 201000007281 estrogen-receptor positive breast cancer Diseases 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 201000004653 inflammatory breast carcinoma Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000003394 isomerase inhibitor Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 102000003998 progesterone receptors Human genes 0.000 description 1
- 108090000468 progesterone receptors Proteins 0.000 description 1
- 201000007282 progesterone-receptor negative breast cancer Diseases 0.000 description 1
- 201000007283 progesterone-receptor positive breast cancer Diseases 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261593108P | 2012-01-31 | 2012-01-31 | |
| US61/593,108 | 2012-01-31 | ||
| PCT/US2013/021402 WO2013115966A1 (en) | 2012-01-31 | 2013-01-14 | Cyclodextrin-based polymers for therapeutic delivery |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015505557A JP2015505557A (ja) | 2015-02-23 |
| JP2015505557A5 true JP2015505557A5 (cg-RX-API-DMAC7.html) | 2016-03-03 |
Family
ID=48870740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014555561A Pending JP2015505557A (ja) | 2012-01-31 | 2013-01-14 | 治療的送達のためのシクロデキストリンに基づく重合体 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20130196946A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2812008A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2015505557A (cg-RX-API-DMAC7.html) |
| CN (1) | CN104203255A (cg-RX-API-DMAC7.html) |
| HK (1) | HK1204962A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013115966A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017177055A1 (en) * | 2016-04-08 | 2017-10-12 | Liang Zhao | Cyclodextrin-based polymers for therapeutic delivery |
| CN110283259B (zh) * | 2019-07-03 | 2021-12-10 | 宁夏医科大学 | 一种解热镇痛布洛芬-β-环糊精第一面衍生物及其制备方法 |
| WO2021005147A1 (en) * | 2019-07-09 | 2021-01-14 | Genesis Pharma Sa | Combination |
| KR20210014368A (ko) * | 2019-07-30 | 2021-02-09 | 한국과학기술원 | 사이클로덱스트린 중합체를 유효성분으로 함유하는 동맥경화증 예방 또는 치료용 약학적 조성물 |
| ES2990069B2 (es) * | 2023-04-24 | 2025-06-04 | Fundacion Univ San Antonio Ucam | Combinacion sinergica para el tratamiento de cancer |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2210258T5 (es) * | 1993-07-29 | 2009-01-16 | The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services | Procedimiento de tratamiento de la ateroesclerosis o reestenosis usando un agente estabilizante de microtubulos. |
| CA2410632A1 (en) * | 2000-06-22 | 2001-12-27 | David S. Garvey | Nitrosated and nitrosylated taxanes, compositions and methods of use |
| EA201200617A1 (ru) * | 2009-11-23 | 2012-11-30 | Серулин Фарма Инк. | Полимеры на основе циклодекстрина для доставки лекарственных средств |
| EP2571525A4 (en) * | 2010-05-18 | 2016-04-27 | Cerulean Pharma Inc | Compositions and methods for treating autoimmune and other diseases |
-
2013
- 2013-01-14 US US13/740,430 patent/US20130196946A1/en not_active Abandoned
- 2013-01-14 HK HK15105727.2A patent/HK1204962A1/xx unknown
- 2013-01-14 WO PCT/US2013/021402 patent/WO2013115966A1/en not_active Ceased
- 2013-01-14 EP EP13743111.0A patent/EP2812008A4/en not_active Withdrawn
- 2013-01-14 CN CN201380017954.7A patent/CN104203255A/zh active Pending
- 2013-01-14 JP JP2014555561A patent/JP2015505557A/ja active Pending
-
2017
- 2017-02-28 US US15/444,802 patent/US20180015170A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jain et al. | Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms | |
| JP2015505557A5 (cg-RX-API-DMAC7.html) | ||
| JP2019504100A5 (cg-RX-API-DMAC7.html) | ||
| TWI854573B (zh) | 藥物組合物、其用途及癌症的治療方法 | |
| RU2017104909A (ru) | Лечение рака комбинацией лучевой терапии, наночастиц оксида церия и химиотерапевтического средства | |
| CN101742910A (zh) | 治疗脑癌的方法 | |
| JP2010520289A5 (cg-RX-API-DMAC7.html) | ||
| WO2005117954A3 (en) | Compositions and methods for treatment of neovascular diseases | |
| CN111558044B (zh) | 一种包含舒尼替尼的药物组合物及其制剂和应用 | |
| JPWO2020260252A5 (cg-RX-API-DMAC7.html) | ||
| Paluri et al. | Second-line treatment for metastatic pancreatic cancer | |
| KR20140143166A (ko) | 조합 요법에 의한 프로카스파제 ３ 활성화 | |
| JP2021501766A5 (cg-RX-API-DMAC7.html) | ||
| Schmitt et al. | Sunitinib plus paclitaxel in patients with advanced esophageal cancer: a phase II study from the Hoosier Oncology Groupe | |
| KR20210019116A (ko) | 카복시아미도트리아졸 오로테이트를 사용하여 화학치료제 및 표적화된 약물에 대해 내성을 획득한 암을 치료하기 위한 방법 및 조성물 | |
| JP2018536655A5 (cg-RX-API-DMAC7.html) | ||
| CN1658880A (zh) | 用于治疗癌症的联合疗法 | |
| JP2007531728A5 (cg-RX-API-DMAC7.html) | ||
| TWI827530B (zh) | 包括對西地尼布進行固定的間歇給藥之方法 | |
| Dutcher et al. | 20th‐Century Advances in Drug Therapy in Oncology—Part II | |
| Wells et al. | Neurotoxicity of biologically targeted agents in pediatric cancer trials | |
| JP5843086B2 (ja) | 治療活性物質の作用を増強するための高分子化環状ニトロキシドラジカル化合物の使用 | |
| EP3228650B1 (en) | Novel peg derivative | |
| Langenberg et al. | Phase 1 study of combination treatment with PTK 787/ZK 222584 and cetuximab for patients with advanced solid tumors: safety, pharmacokinetics, pharmacodynamics analysis | |
| JPWO2015125641A1 (ja) | 高分子化カンプトテシン誘導体及び高分子化ｈｓｐ９０阻害剤誘導体を含む医薬組成物 |